SGN-B6A is an ADC that targets integrin β-6 (ITGB6) via the human IgG1 monoclonal antibody Sigvotatug and exhibits cytotoxicity against a variety of integrin β-6-positive cancer cells via the mitotic inhibitor MMAE.

Physicochemical Properties

Appearance	Colorless to light yellow liquid
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

References

[1]. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453.

Solubility Data